Nextech Venture, Ltd.

Nextech Venture, Ltd. is a global venture capital firm specializing in oncology-focused investments. Established in 1998 and headquartered in Zurich, Switzerland, the firm manages and advises multiple life science venture capital funds, with a particular emphasis on cancer therapeutics. Supported by a distinguished Scientific Advisory Board of leading oncologists, Nextech Venture seeks to bridge the translational gap in oncology by investing in emerging companies with pioneering innovations in cancer research, particularly those with compounds entering advanced clinical trials.

The firm's investment strategy focuses on early-stage companies developing novel cancer therapies, diagnostics, and medical devices. By providing capital and strategic support, Nextech Venture aims to accelerate the development of groundbreaking oncology treatments. The firm is an active member of leading private equity networks, including the European Private Equity and Venture Capital Association (EVCA) and the Swiss Private Equity and Corporate Finance Association (SECA), and collaborates closely with the Union for International Cancer Control (UICC).

Nextech Venture's portfolio includes investments in companies such as MacroGenics, a biopharmaceutical firm specializing in oncology therapeutics. The firm's approach combines financial investment with scientific expertise to drive value creation for its portfolio companies, aiming to bring innovative cancer treatments to market more efficiently and effectively.